ProCE Banner Activity

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Slideset

Downloadable slideset from Komal Jhaveri, MD, FACP, on the role of TROP-2‒directed antibody‒drug conjugates in the therapeutic landscape for patients with HER2-negative advanced breast cancer, including HER2-low disease.

Released: February 22, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.